Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas. [electronic resource]
Producer: 20090602Description: 4352-61 p. digitalISSN:- 1528-0020
- Animals
- Antibodies, Monoclonal -- therapeutic use
- Antibodies, Monoclonal, Murine-Derived
- Antigens, CD19 -- immunology
- Antineoplastic Agents -- therapeutic use
- Blotting, Western
- Cell Line, Tumor
- Cell Survival
- Citrulline -- chemistry
- Dimerization
- Dipeptides -- metabolism
- Drug Resistance, Neoplasm
- Female
- Flow Cytometry
- Gene Dosage
- Humans
- Immunoconjugates -- therapeutic use
- Immunoenzyme Techniques
- Lymphoma, Non-Hodgkin -- drug therapy
- Lysosomes
- Mice
- Mice, SCID
- Oligopeptides -- metabolism
- Receptors, Complement 3d -- genetics
- Rituximab
- Valine -- chemistry
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.